Oral sildenafil (Viagra) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital.

"Competing interests We are grateful to Pfizer plc for providing an independent educational grant towards the Research Fellowship of KS. Pfizer plc have neither contributed nor influenced the material data or conclusions of this study. Table 4Patient demographics. Ranges and percentages are provided in parentheses.Mean age of patients in years56.3 (18 – 85)Race Caucasians137 Blacks5 Asians5Sexual orientation Heterosexuals142 Homosexuals5Mean duration of ED in years4.7 (0.5 – 20)Lack of libido9 (6.1%)Lack of nocturnal tumescence or early morning erections43 (29.3%)Reported frequency of sexual intercourse (per week) – mean2.4 (0.25 – 10)Aetiological groups Vasculogenic39 (26.5%) Psychogenic42 (28.6%) Neurogenic4 (2.7%) Mixed42 (28.6%) Diabetes17 (11.6%) Hypogonadism2 (1.4%) Drug induced1 (0.7%)Comorbidity Known diabetics22 (15%) Known hypertension27 (18.4%) Ischaemic heart disease (known angina / MI / treated for IHD)15 (10.2%) Known arrythmia (with or without treatment)8 (5.4%)Peripheral vascular disease15 (10.2%) Congestive heart failure2 (1.4%) Low testosterone (proven on fasting sample; below normal or treated by GP with androgens for hypogonadism)40 (31%, n = 129) Dyslipidemia (proven by blood test or on prophylactic statins)18 (12.2%)Alcohol consumption > 21 units per week13 (8.8%)Smokers45 (30.6%)Ex-smokers65 (44.2%)Non-smokers37 (25.2%)"